Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G1 cell cycle arrested

Lü, Li; Yang, Li-Ning; Wang, Xuexi; Song, Chunli; Qin, Hong; Wu, Yongjie

doi:10.1007/s11655-016-2591-1

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate the effects of the drugs in combination, we calculated the coefficient of drug interaction (CDI) using the formula CDI=AB/(A×B), where AB is the tumor volume ratio of the combination group to the control group, and A and B are the tumor volume ratios of the single agent groups to the control group. A CDI value <1, =1 or >1 indicates synergistic, additive or antagonistic effects, respectively, which a CDI <0.7 indicating a significant synergistic effect ( 20 ).…”

Section: Methodsmentioning

confidence: 99%

Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells

Li¹,

Xie²,

Wang³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: To observe the effect of bevacizumab in combination with β-elemene on subcutaneousxenografts established from HCT-116 human colon cancer cells, explore the underlying mechanisms involved, and provide more options for the treatment of advanced colorectal cancer.Methods: Mice were randomly divided into four groups: control, β-elemene, bevacizumab and combination treatment. Tumor volume was measured and the tumor inhibition rate and coefficient of drug interaction (CDI) were calculated. The pathological and morphological features of the tumor tissues were observed.Protein expression levels of ki-67, CD31, vascular endothelial growth factor (VEGF) and bcl-2 were measured by immunohistochemistry.Results: The tumor volumes in the four groups were 0.991±0.131, 0.833±0.145, 0.563±0.131 and 0.324±0.066 cm 3 , respectively. The tumor inhibition rates in the β-elemene, bevacizumab and combination groups were 15.9%, 43.2% and 67.3%, respectively. The degree of tumor reduction in the combination group was the most significant (P<0.05), with a CDI of 0.697. Immunohistochemistry showed that the ki-67 proliferation indexes in the four groups were 30.06%±3.37%, 19.79%±3.75%, 27.51%±2.16% and 16.9%±1.09%, the microvessel densities (MVDs) were 45.86±9.28, 31.14±5.58, 27.57±6.11 and 12.14±3.53, the rates of positive VEGF expression were 39.48%±6.72%, 28.86%±3.54%, 25.04%±2.64% and 19.5%±2.68%, and the rates of positive bcl-2 expression were 33.95%±6.38%, 20.11%±9.49%, 24.28%±6.57% and 11.18%±2.72%, respectively. Compared with the control group, the three experimental groups displayed different degrees of reduction in the above indicators (P<0.05), with the combination group exhibiting the lowest values (P<0.05).Conclusions: Bevacizumab exerts a synergistic effect with β-elemene in suppressing the growth of tumors derived from HCT-116 cells, and the related mechanisms may include the inhibition of tumor cell proliferation and tumor angiogenesis and the promotion of tumor cell apoptosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells

Li¹,

Xie²,

Wang³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Furthermore, we analyzed the coefficient of drug interaction (CDI) metric. Dose-dependent effects of AR-42 and DDP at fixed dose ratios were calculated using the CDI value that identified dual-drug synergism, antagonism, or additivity (L. Lu et al, 2017;Zheng et al, 2016). The CDI value was calculated according to the following formula: CDI = AB/(A*B).…”

Section: Analysis Of Drug Interactions In Vitromentioning

confidence: 99%

Histone deacetylase inhibitor, AR‐42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells

Duan

Gong

Liu

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Retinoblastoma (RB) is the most common type of intraocular malignant tumor that occurs in childhood. AR-42, a member of a newly discovered class of phenylbutyratederived histone deacetylase inhibitors, exerts antitumor effects on many cancers. In the present study, we initially evaluated the effect of AR-42 towards RB cells and explored the underlying mechanism in this disease. Our results found that AR-42 showed powerful antitumor effects at low micromolar concentrations by inhibiting cell viability, blocking cell cycle, stimulating apoptosis in vitro, and suppressing RB growth in a mouse subcutaneous tumor xenograft model. Furthermore, the AKT/ nuclear factor-kappa B signaling pathway was disrupted in Y79 cells treated with AR-42. In conclusion, we propose that AR-42 might be a promising drug treatment for RB. K E Y W O R D SAKT/NF-κB, AR-42, retinoblastoma, Y79

show abstract

“…Ampelopsin has been indeed shown to inhibit proliferation, induce apoptosis, suppress migration, invasion and metastasis in various types of tumoral cells [17] , [18] , [27] , [28] . Moreover, treatment of malignant cells with ampelopsin was also demonstrated to confer overcoming resistance and potentiating the responses to standard anticancer drugs like erlotinib [29] or carboplatin [30] , opening new avenues in cancer treatment. Therefore, in this review article the molecular mechanisms behind these promising effects are described in depth.…”

Section: Introductionmentioning

confidence: 99%

Ampelopsin targets in cellular processes of cancer: Recent trends and advances

Tuli

Sak²,

Garg

et al. 2022

Toxicology Reports

View full text Add to dashboard Cite

Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G1 cell cycle arrested

Abstract: Amp-Na exhibits anticancer activities and enhances the antitumor activities of CBP through up-regulation of p21 and inhibition of CDK2 activity in human NSCLC cells SPC-A1. These results suggest that Amp-Na may be applied to enhance the anticancer action of CBP.

Cited by 7 publications

References 23 publications

Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells

Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells

Histone deacetylase inhibitor, AR‐42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells

Ampelopsin targets in cellular processes of cancer: Recent trends and advances

Contact Info

Product

Resources

About